EU Regulators Recommend Lilly's Jaypirca for Broad CLL Approval
Summary
The CHMP has recommended Eli Lilly's Jaypirca for approval in the European Union for adults with Chronic Lymphocytic Leukemia (CLL) across all lines of therapy. This is a significant positive regulatory step, paving the way for full EU market access for this new oncology drug. A final decision from the European Commission is expected within one to two months. Lilly has also submitted Jaypirca for FDA approval in CLL, with a decision anticipated in the second half of 2026.
At the time of this announcement, LLY was trading at $1,124.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.